National Academies Press: OpenBook

Vaccines for the 21st Century: A Tool for Decisionmaking (2000)

Chapter: Appendix 23: Shigella

« Previous: Appendix 22: Rotavirus
Suggested Citation:"Appendix 23: Shigella." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×

APPENDIX 23
Shigella

DISEASE BURDEN

Epidemiology

For the purposes of the calculations in this report, the committee estimated that there are approximately 30,000 new cases of shigella disease each year in the United States. It is assumed that the highest incidence is in children between the ages of 1 and 4 years of age. Children under one year of age and between 5 and 14 years of age also contribute heavily to the number of cases. It is assumed that there are no deaths associated with shigella infection in the United States. It was assumed that 25% of cases are in travelers from the United States to other countries.

Disease Scenarios

For the purposes of the calculation in this report, the committee assumed that shigella manifests as acute diarrhea lasting 6 days and associated with a health utility index of .51.

COST INCURRED BY DISEASE

For the purposes of the calculations in this report, it was assumed that 25% of people with shigella incur costs associated only with over-the-counter treatment, such as oral rehydration or anti-diarrheals. It was assumed that 75% of

Suggested Citation:"Appendix 23: Shigella." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×

people with shigella infection seek the care of a physician and receive medication. See Table A23–1.

VACCINE DEVELOPMENT

The committee assumed that it will take 7 years until licensure of a shigella vaccine and that $240 million needs to be invested. It was assumed that research into the development of a shigella vaccine would lead to increased knowledge of mucosal immunity, which would benefit research and development of many vaccines in the future. Table 4–1 summarizes vaccine development assumptions for all vaccines considered in this report.

VACCINE PROGRAM CONSIDERATIONS

Target Population

For the purposes of the calculations in this report, two scenarios are discussed: a target population of travelers only and a target population of travelers and infants. It is assumed that 90% of infants and 30% of travelers will accept the vaccine.

Vaccine Schedule, Efficacy, and Costs

For the purposes of the calculations in this report, it was estimated that this vaccine would cost $50 per dose and that administration costs would be $10 per dose. Default assumptions of a 3-dose series and 75% effectiveness were accepted. Table 4–1 summarizes vaccine program assumptions for all vaccines considered in this report.

RESULTS

If a vaccine program for Shigella were implemented today and the vaccine were 100% efficacious and utilized by 100% of the target population, the annualized present value of the QALYs gained would be 160. Using committee assumptions of less-than-ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the QALYs gained would be 57.

If a vaccine program for Shigella were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the health care costs saved would be $1.7 million.

Suggested Citation:"Appendix 23: Shigella." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×

Table A23–1 Health Care Costs Associated with Shigella Infection

 

% of Cases

Cost per Unit

Units per Case

Form of Treatment

Acute diarrhea

25%

$10

2.0

oral rehydration therapy

 

75%

$50

1.0

physician a

75%

$50

1.0

medication b

Using committee assumptions of less-than-ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the health care costs saved would be $620,000.

If a vaccine program for Shigella were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the program cost would be $1.2 billion. Using committee assumptions of less-than-ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the program cost would be $550 million.

Using committee assumptions of time and costs until licensure, the fixed cost of vaccine development has been amortized and is $7.2 million for a Shigella vaccine.

If a vaccine program were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the cost per QALY gained is $7 million. Using committee assumptions of less-than-ideal utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the cost per QALY gained is $9 million. If the vaccine were utilized by 90% of travelers (and no infants) the annualized present value of the cost per QALY gained is $11 million.

See Chapters 4 and 5 for details on the methods and assumptions used by the committee for the results reported.

READING LIST

Ashkenazi S, Cleary TG. Shigella Infections. In: Textbook of Pediatric Infectious Diseases. RD Feigin and JD Cherry eds. Philadelphia, PA: WB Saunder Company, 1992, pp. 637–646.


CDC. Summary of Notifiable Diseases, United States 1994. Morbidity and Mortality Weekly Report 1994; 43:1–80.


DuPont HL. Shigella Species (Bacillary Dysentery). In: Principles and Practice of Infectious Diseases. GL Mandell, JE Bennett, Dolin R eds. New York, NY: Churchill Livingstone, 1995, pp. 2033–2039.

Suggested Citation:"Appendix 23: Shigella." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
This page in the original is blank.
Suggested Citation:"Appendix 23: Shigella." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 295
Suggested Citation:"Appendix 23: Shigella." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 296
Suggested Citation:"Appendix 23: Shigella." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 297
Suggested Citation:"Appendix 23: Shigella." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 298
Next: Appendix 24: Streptococcus, Group A »
Vaccines for the 21st Century: A Tool for Decisionmaking Get This Book
×
Buy Hardback | $72.95 Buy Ebook | $59.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Vaccines have made it possible to eradicate the scourge of smallpox, promise the same for polio, and have profoundly reduced the threat posed by other diseases such as whooping cough, measles, and meningitis.

What is next? There are many pathogens, autoimmune diseases, and cancers that may be promising targets for vaccine research and development.

This volume provides an analytic framework and quantitative model for evaluating disease conditions that can be applied by those setting priorities for vaccine development over the coming decades. The committee describes an approach for comparing potential new vaccines based on their impact on morbidity and mortality and on the costs of both health care and vaccine development. The book examines:

  • Lessons to be learned from the polio experience.
  • Scientific advances that set the stage for new vaccines.
  • Factors that affect how vaccines are used in the population.
  • Value judgments and ethical questions raised by comparison of health needs and benefits.

The committee provides a way to compare different forms of illness and set vaccine priorities without assigning a monetary value to lives. Their recommendations will be important to anyone involved in science policy and public health planning: policymakers, regulators, health care providers, vaccine manufacturers, and researchers.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!